Recida Therapeutics

About Us

Recida Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria.

Press Releases

Menlo Park, April 1, 2019 — Recida Therapeutics, Inc. announced today the initiation of a Phase I trial for RC-01, a novel LpxC inhibitor. 

 

Pipeline

RC-01, a novel LpxC inhibitor, displays highly potent inhibitory activity against the bacterial LpxC enzyme with an IC50 at subnanomolar levels.